Checkpoint Therapeutics Appoints Amit Sharma, MD, to Board

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, has announced that Amit Sharma, MD, FACP, FASN, FNKF, has joined its board as an independent, nonexecutive director.

Dr. Sharma received his medical degree from Louisiana State University Medical Center in New Orleans and completed his nephrology and hypertension fellowship at the University of California, San Diego. He is certified by the American Board of Internal Medicine for internal medicine and nephrology and has an additional certification as a hypertension specialist by the American Society of Hypertension.

Dr. Sharma has held various senior leadership roles at biotechnology companies and larger pharmaceutical companies. Currently, he is vice president of clinical development and therapeutic head for nephrology and hematology at Alexion, AstraZeneca Rare Disease. There, he guides and executes the strategic direction of products and programs within Alexion’s nephrology franchise across all stages of development. Before joining Alexion, Dr. Sharma was vice president of medical affairs for the cardiovascular and renal division of Bayer Pharmaceuticals.

“We are pleased to welcome Dr. Sharma to our Board of Directors,” said James F. Oliviero, president and chief executive officer of Checkpoint. “He is a highly accomplished life sciences executive, with leadership experience in many facets of both patient care and the research, development, approval, and commercialization of pharmaceutical products.”